The week in health tech, explained in plain English.Get the free newsletter →
October 26, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Hospitals

New Mexico's Plains Regional Medical Center CEO Exits

By Healthcare Technology News ·

Bill Priest, chief executive of Plains Regional Medical Center in Clovis, New Mexico, is no longer with Albuquerque-based Presbyterian Healthcare Services, according to Becker's Hospital Review. Priest led the hospital for three years.

Todd Oberheu, Presbyterian's vice president of operations for its regional delivery system, credited Priest with helping teams navigate the post-pandemic transition and thanked him for his service to the hospital and community. The system did not detail a reason for the departure or name a permanent successor.

The move fits a broader pattern of leadership churn at rural and regional hospitals, where executives face thin margins, staffing shortages, and pressure to stabilize operations after the pandemic. Presbyterian is one of New Mexico's largest health systems, operating hospitals and a health plan across the state. Continuity at facilities like PRMC, often the primary care option for surrounding rural communities, matters for patients who have few alternatives nearby.

Sources

More in Hospitals

Hospitals

Visitor Fatally Shot at HCA Missouri Hospital; Patient Charged

A visitor was fatally shot at HCA Healthcare's Centerpoint Medical Center in Missouri, and patient James Lawson faces second-degree murder charges.

Why it matters: Violence inside hospitals is driving systems to rethink weapons screening and access control to protect patients, staff, and visitors.

Hospitals

Pay Dispute Puts Illinois Hospital's Trauma Status at Risk

An Illinois hospital's level 2 trauma designation is under state review after its anesthesia group suspended services over a missed payment.

Why it matters: A single vendor contract breakdown can strip a hospital of its trauma status and leave a community without nearby emergency surgical care.

Hospitals

Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

Merck and Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in a phase 3 trial when paired with Keytruda immunotherapy.

Why it matters: A successful phase 3 readout signals that personalized mRNA cancer vaccines are nearing clinical reality for high-risk cancer patients.